 |
 |
 |
 |
 |
|
|
|
|
|
|
|
Charles Grob, MD. Grob is one of the only researchers in the United States to have administered MDMA to human subjects. Here he comments on the FDA's attitude toward the Harbor UCLA MDMA research being planned to investigate the safety of MDMA therapy in cancer patients.
MAPS has been working since its founding in 1986 to obtain permission to study the therapeutic use of MDMA in cancer patients. On June 24, 1999, a teleconference took place between several FDA officials and Rick Doblin, Dr. Grob, Loren Miller (a consultant assisting MAPS on protocol design and FDA relations issues) and Matt Baggott. According to the memorandum of that teleconference prepared by the FDA, " The Center [FDA's Center for Drug Evaluation and Research, which is in charge of research on all new drugs for humans] has decided to allow the sponsor [MAPS] to undertake a proof of principle study..." More details on this There are lots of details left to determine and negotiate before the study can happen. This FDA decision about MDMA research suggests that the FDA really will prioritize science over ideology, a position that NIDA only espouses rhetorically.
|
* Read more about research at Harbor UCLA under the direction of Dr. Grob.
 |